SEMIFLUORINATED COMPOUNDS AND THEIR COMPOSITIONS

• US 20170087100A1
• Filed: 09/29/2016
• Published: 03/30/2017
• Est. Priority Date: 09/30/2015
• Status: Abandoned Application

• Current Assignee: Novaliq GmbH
• Original Assignee: Novaliq GmbH
• Inventors: SCHERER, Dieter, GRILLENBERGER, Ralf, LSCHER, Frank, VOSS, Hartmut
• Application Number:
  US15/280,306
• Publication Number:
  US 20170087100A1
• Time in Patent Office: Days
• US Class Current: 1/1
• CPC Class Codes: A61F 9/0008 Introducing ophthalmic products into the ocular cavity or retaining products therein putting in contact lenses A61F9/0061; introducing or retaining media in cavities of the body in general A61M31/00
• CPC Class Codes: A61K 31/02 Halogenated hydrocarbons
• CPC Class Codes: A61K 9/0048 Eye, e.g. artificial tears
• CPC Class Codes: A61K 9/08 Solutions composition of solutions A61K47/00
• CPC Class Codes: A61P 27/02 Ophthalmic agents

Abstract

The present invention is directed to compositions comprising semifluorinated compounds and their use as medicaments for topical administration to the eye.

Claims

1. A composition comprising CF₃(CF₂)₅(CH₂)₇CH₃ and CF_3-(CF₂)_5-CH(CH₃)—

(CH₂)₅—

CH₃.

2. The composition according to claim 1, comprising at least about 80 wt % of CF₃(CF₂)₅(CH₂)₇CH₃.

3. The composition according to claim 1, comprising up to about 25 wt % of CF₃—

(CF₂)₅—

CH(CH₃)—

(CH₂)₅—

CH₃.

4. The composition according to any preceding claim 1 comprising about 97 wt % of CF₃(CF₂)₅(CH₂)₇CH₃ and up to about 3 wt % of CF₃—

(CF₂)₅—

CH(CH₃)—

(CH₂)₅—

CH₃.

5. The composition according to claim 1, being formulated as a clear liquid solution.

6. The composition of claim 1, being substantially free of:

(a) a polymer,

(b) a perfluorinated compound, and/or

(c) a dissolved pharmacologically active ingredient.

7. The composition of claim 1, having a dynamic viscosity of not more than 10 mPa·

s, and preferably not more than 4 mPa·

s, at ambient temperature and pressure.

8. A method of treating a disease or condition of a patient in need of such treatment, comprising administering the composition according to claim 1 to the patient.

9. The method according to claim 8, wherein the composition is topically administered to a lacrimal sac, into a lower eyelid, to an eye surface, or to an ophthalmic tissue.

10. The method according to claim 8, wherein the composition is administered up to four times per day.

11. The method according to claim 8, wherein the disease or condition to be treated is keratoconjunctivitis sicca or a symptom or condition associated therewith, and/or Meibomian Gland Dysfunction (MGD).

12. The method according to claim 8, wherein the composition is administered to lubricate the eye surface.

13. The method according to claim 8, wherein the condition to be treated is corneal damage.

14. A kit comprising a composition according to claim 1 and a container for holding the composition, wherein said container comprises a dispensing means adapted for topical administration of the composition to a lacrimal sac, into a lower eyelid, to an eye surface, or to an ophthalmic tissue.

15. The kit of claim 14, wherein the dispensing means comprises a dropper dimensions such as to dispense droplets having a volume of 8 to 15 μ

L.

16. The composition according to claim 1 consisting of about 97 wt % of CF₃(CF₂)₅(CH₂)₇CH₃ and up to about 3 wt % of CF₃—

(CF₂)₅—

CH(CH₃)—

(CH₂)₅—

CH₃.

17. The composition according to claim 3, being formulated as a clear liquid solution.

18. The composition of claim 4, being substantially free of:

(a) a polymer,

(b) a perfluorinated compound, and/or

(c) a dissolved pharmacologically active ingredient.

19. The composition of claim 5, being substantially free of:

(a) a polymer,

(b) a perfluorinated compound, and/or

(c) a dissolved pharmacologically active ingredient.

20. The composition according to claim 18, being formulated as a clear liquid solution.